Novo Nordisk Narrows Saxenda’s Positioning, Targets Seriously Ill Patients
This article was originally published in The Pink Sheet Daily
The Danish diabetes specialist is preparing to diversify into obesity with the first launches of Saxenda expected in the first half of 2015. Competition is expected to increases for GLP-1 market leader Victoza but Novo Nordisk also expects a more benign U.S. pricing environment during the year.
You may also be interested in...
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.
Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.